FDA Brief

Warning letters Drugs

FDA warning letter to

Adamson Analytical Laboratories, Inc.

High riskIssued Aug 17, 2021Posted Nov 9, 2021Division of Pharmaceutical Quality Operations IV

FDA warned California contract drug-testing lab Adamson over inadequate computer controls and data integrity failures.

What happened

FDA inspected Adamson Analytical Laboratories in Corona, California, from March 8 to 23, 2021. FDA found that the lab's gas and liquid chromatography systems lacked adequate controls over electronic data, including audit trails (records of who did what and when) that were not activated and analyst administrative privileges that allowed data deletion or alteration; it also found unvalidated electronic worksheets used for microbial testing. FDA called the computer-control issue a repeat violation from a 2016 warning letter and said the company's April 13, 2021, response was inadequate.

What FDA found

  1. The lab did not adequately control its computer systems, allowing analysts to delete or change data and leaving audit trails off on chromatography instruments.

    21 CFR 211.68(b)
  2. The lab used unvalidated electronic worksheets for microbial challenge testing, producing erroneous calculations.

    21 CFR 211.68(b)
  3. The lab made critical changes to laboratory operations without review or approval by its quality group.

    21 CFR 211.160(a)
  4. The lab activated instrument audit trails in February 2021 without governing procedures or change control.

    21 CFR 211.160(a)
  5. The lab did not review audit trail data before releasing analytical results, though batch release data review requires it.

    21 CFR 211.22
  6. The computer-control failure was a repeat violation from a 2016 warning letter, and promised corrections were not fully implemented.

    21 CFR 211.68(b)

What FDA wants

FDA tells Adamson to correct the violations promptly and respond in writing within 15 working days with corrective actions, including lists of instruments and user privileges, an independent change-management assessment, and data-integrity remediation. FDA also strongly recommends a qualified consultant.

Who should pay attention

  • drug manufacturers and brands that use this contract testing lab
  • companies relying on Adamson's analytical or microbial test data for release
  • quality teams managing contract laboratories and data integrity

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Pritam International Private Limited

    Pritam International, an Indian OTC drug maker, was cited for CGMP violations, falsified lab data, unsafe color additive, and DEG/EG testing gaps.

    High risk
  3. Conroe Welding Supply, Inc.

    FDA warns Conroe Welding Supply over medical oxygen manufacturing failures, including untested batches and a container with 99% (b)(4).

    High risk
  4. SnugZ USA, Inc.

    SnugZ USA, an OTC drug maker in West Jordan, Utah, was cited for releasing drugs after retesting failed batches until they passed.

    High risk